Back to Awarded Treatment Trials
Awarded Trial: 11T-012
Grant ID
11T-012
Illness
schizophrenia
Primary Drug/Intervention
oxytocin
Primary Dosage
24 IU/tid
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Weiser
Sample Size
48
Duration of Study Period for Each Subject
21
Outcome Measurements
Change in the total score of structured assessment of social interaction in OT copared with placebo on all patients
Results
In a 2X2 design, 48 patients with schizophrenia or schizoaffective disorder were randomized to add-on treatment of intranasal oxytocin or placebo, and to either social skills training or supportive therapy, for a period of three weeks. No significant change was found in the primary outcome measure of social interaction, nor in the emotion battery or PANSS assessment from baseline to week 3 in any of the groups.
Publication
N/A
Link
N/A
PI Name
Mark Weiser
Degree
MD
Center
N/A
Institution
Sheba Medical Center
Address
Tel Hashomer
City or Town
Ramat Gan
State or Province
N/A
Zip or Postal Code
52621
Country
Israel
Email Address
mweiser@013net.net